About this trial
Any patient with a suspected primary adenocarcinoma of the colon, sigmoid or rectum undergoing surgery are eligible. The date of surgery must be known prior to registration. This trial aims to determine if image mapping techniques can improve the concordance between imaging and pathology detection of tumour deposits. Lymph nodes and tumour deposits will be identified on pre-operative scans and mapped by radiologists then shared with pathologists prior to processing the resected specimen. Patients will be managed at their local hospital with standard follow-up. Patients will be followed up for 5 years.
Eligibility criteria
Qualifiers
Suspected primary adenocarcinoma of the colon, sigmoid or rectum (proven by biopsy taken as part of routine clinical practice, patients to be withdrawn if not subsequently adenocarcinoma on pathology).
Amenable to surgical resection.
Disease spread assessed on imaging
Patients having primary surgery and those undergoing neoadjuvant treatment will be included.
Disqualifiers
Patients with recurrent tumours
Synchronous tumours
Under the age of 16 years
Unable to give informed consent.
Trial design
Treatments tested in this trial
- MRI mapping to guide pathological sampling of extranodal tumour deposits
Treatment groups
Sponsors and collaborators
Imperial College London
Lead sponsor
Pelican Cancer Foundation
Collaborator